Tag: GM1
Lysogene Announces Positive DSMB Findings Recommending Study Continuation and Positive Biomarker Data in Phase 1 of Adaptive Gene Therapy Clinical Trial with LYS-GM101 for the Treatment of GM1 Gangliosidosis – 11/29/ 2022 at 6:00 PM
• Finalization of the treatment and follow-up at 6 months of the last patient recruited in the first phase of the adaptive clinical trial P1-GM-101 • The DSMB gave a…
Lysogene receives MHRA UK Innovation Passport for its gangliosidosis program at GM1 – 12/20/2021 at 08:00
To receive all of Lysogene’s financial information in real time, send a request by email to [email protected] This approach is part of the recent initiative of the British MHRA to…